Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,175Revenue (TTM) $M88.1Net Margin (%)266Altman Z-Score4.9
Enterprise Value $M2,276EPS (TTM) $10.8Operating Margin %44.4Piotroski F-Score6
P/E(ttm)9.6Beneish M-Score0.3Pre-tax Margin (%)14.8Higher ROA y-yY
Price/Book5.610-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsN
Price/Sales25.55-y EBITDA Growth Rate %--Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow126y-y EBITDA Growth Rate %91.7ROA % (ttm)45.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)80.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M20.9ROIC % (ttm)87.1Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2016-06-30 Add0.07%$107.09 - $130.37
($118.77)
$ 104.31-12%Add 229.35%71,870
LGNDKen Fisher 2016-06-30 Add$107.09 - $130.37
($118.77)
$ 104.31-12%Add 2.56%72,390
LGNDJoel Greenblatt 2016-03-31 Buy 0.03%$85.79 - $108.42
($97.41)
$ 104.317%New holding21,822
LGNDKen Fisher 2015-12-31 Reduce$85.69 - $111.85
($99.19)
$ 104.315%Reduce -0.14%70,583
LGNDKen Fisher 2015-09-30 Reduce$82.1 - $111.25
($97.26)
$ 104.317%Reduce -12.31%70,683
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 104.3119%Reduce -1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 104.3170%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 104.31100%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 104.31100%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 104.3197%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 104.3160%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 104.3160%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 104.3157%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 104.3199%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 104.31131%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 104.31691%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 104.31889%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 104.31759%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 104.31545%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FOEHR MATTHEW WPresident and COO 2016-08-05Sell12,500$122.14-14.6view
Berkman Charles SVP, Gen. Counsel & Secretary 2016-08-05Sell22,067$123.16-15.31view
KOZARICH JOHN WDirector 2016-08-01Sell1,000$137.57-24.18view
KOZARICH JOHN WDirector 2016-07-01Sell1,000$121.4-14.08view
KOZARICH JOHN WDirector 2016-06-01Sell1,000$117.42-11.17view
Herman Melanie JDirector of Accounting 2016-05-18Sell334$120.5-13.44view
Aryeh JasonDirector 2016-05-06Sell25,000$119.2-12.49view
KOZARICH JOHN WDirector 2016-05-02Sell1,000$121.57-14.2view
KOZARICH JOHN WDirector 2016-04-06Sell5,000$115-9.3view
FOEHR MATTHEW WPresident and COO 2016-03-17Sell6,400$96.77.87view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Aug 26 2016
ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016 Aug 24 2016
Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next? Aug 19 2016
VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to... Aug 16 2016
Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in... Aug 15 2016
LIGAND PHARMACEUTICALS INC Financials Aug 12 2016
Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard,... Aug 12 2016
Ligand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says Aug 11 2016
5 Stocks to Play Momentum the Driehaus Way Aug 11 2016
ETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 9, 2016 Aug 09 2016
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US :... Aug 09 2016
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 Aug 08 2016
Ligand Pharma downgraded by Deutsche Bank Aug 05 2016
Edited Transcript of LGND earnings conference call or presentation 4-Aug-16 1:00pm GMT Aug 05 2016
Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View Aug 05 2016
Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y Aug 04 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 04 2016
Ligand reports 2Q loss Aug 04 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)